HU230174B1 - Rapamycin-származékot tartalmazó ömlesztett keverék - Google Patents
Rapamycin-származékot tartalmazó ömlesztett keverék Download PDFInfo
- Publication number
- HU230174B1 HU230174B1 HU1300289A HUP1300289A HU230174B1 HU 230174 B1 HU230174 B1 HU 230174B1 HU 1300289 A HU1300289 A HU 1300289A HU P1300289 A HUP1300289 A HU P1300289A HU 230174 B1 HU230174 B1 HU 230174B1
- Authority
- HU
- Hungary
- Prior art keywords
- ethyl
- hydroxy
- rapamycin
- mixture
- crystalline form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 33
- 229960002930 sirolimus Drugs 0.000 title claims description 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims description 10
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims description 9
- 239000013078 crystal Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
- 238000002425 crystallisation Methods 0.000 claims 4
- 239000000047 product Substances 0.000 claims 4
- 230000008025 crystallization Effects 0.000 claims 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 241001116389 Aloe Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 150000007824 aliphatic compounds Chemical class 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract description 14
- 229940041033 macrolides Drugs 0.000 abstract description 3
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 150000004291 polyenes Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9826882.4 | 1998-12-07 | ||
| GBGB9826882.4A GB9826882D0 (en) | 1998-12-07 | 1998-12-07 | Organic compounds |
| GBGB9904934.8A GB9904934D0 (en) | 1998-12-07 | 1999-03-04 | Organic compounds |
| GB9904934.8 | 1999-03-04 | ||
| PCT/EP1999/009521 WO2000033878A2 (en) | 1998-12-07 | 1999-12-06 | Stabilization of macrolides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU230174B1 true HU230174B1 (hu) | 2015-09-28 |
Family
ID=26314797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU1300289A HU230174B1 (hu) | 1998-12-07 | 1999-12-06 | Rapamycin-származékot tartalmazó ömlesztett keverék |
| HU0104489A HU228939B1 (en) | 1998-12-07 | 1999-12-06 | Stabilization of derivative of rapamicin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104489A HU228939B1 (en) | 1998-12-07 | 1999-12-06 | Stabilization of derivative of rapamicin |
Country Status (38)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| MXPA04007847A (es) | 2002-02-13 | 2005-02-24 | Biogal Gyogyszergyar | Metodo para extraer un macrolido de biomateria. |
| US7452692B2 (en) | 2002-02-13 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Method for extracting a macrolide from biomatter |
| AR040693A1 (es) * | 2002-07-30 | 2005-04-13 | Wyeth Corp | Formulaciones parenterales |
| WO2004089958A2 (en) * | 2003-03-31 | 2004-10-21 | TEVA Gyógyszergyár Részvénytársaság | Crystallization and purification of macrolides |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| PL1558622T3 (pl) | 2003-07-24 | 2008-06-30 | Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag | Sposób oczyszczania makrolidów |
| KR20060085246A (ko) | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| US9114198B2 (en) * | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
| KR20060126701A (ko) * | 2003-12-10 | 2006-12-08 | 애크럭스 디디에스 피티와이 리미티드 | 경피 또는 국소 약물 전달에 따른 원치않는 효과의치료방법 |
| US8551512B2 (en) * | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
| MX2007003731A (es) * | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| WO2007067566A2 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
| US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
| US20070142422A1 (en) * | 2005-12-20 | 2007-06-21 | Wyeth | Control of CCI-779 dosage form stability through control of drug substance impurities |
| KR20140093764A (ko) * | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| JP2013527223A (ja) | 2010-06-02 | 2013-06-27 | フレゼニウス・カビ・オンコロジー・リミテッド | ラパマイシンエステルの安定な医薬組成物 |
| CN103025753A (zh) * | 2010-06-07 | 2013-04-03 | 泰立克公司 | 晶体盐酸依泽替米贝非溶剂化物 |
| WO2012017449A1 (en) * | 2010-08-04 | 2012-02-09 | Meril Life Sciences Pvt. Ltd | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| ES2753529T3 (es) | 2010-11-19 | 2020-04-13 | Biocon Ltd | Procesos para la preparación de everolimús y productos intermedios del mismo |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| WO2013022201A1 (en) * | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| US9610385B2 (en) | 2013-03-07 | 2017-04-04 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device comprising a rapamycin derivative |
| IN2013MU02532A (https=) | 2013-07-31 | 2015-06-26 | Sahajanand Medical Technologies Pvt Ltd | |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| CN104892632B (zh) * | 2015-06-03 | 2017-12-26 | 道中道（菏泽）制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
| EP3329916A4 (en) | 2015-07-28 | 2019-03-20 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME |
| JP6793651B2 (ja) * | 2015-08-28 | 2020-12-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| US20190038605A1 (en) * | 2015-09-18 | 2019-02-07 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof |
| WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
| WO2017204215A1 (ja) | 2016-05-27 | 2017-11-30 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| KR102051806B1 (ko) * | 2018-01-12 | 2019-12-04 | 주식회사 종근당 | 에베로리무스를 포함하는 안정화된 약제학적 제제 |
| EP4126882A1 (en) * | 2020-03-27 | 2023-02-08 | Boston Scientific Scimed Inc. | Methods for crystallization of drugs |
| JP2023028473A (ja) * | 2021-08-19 | 2023-03-03 | 日本マイクロバイオファーマ株式会社 | エベロリムスの製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3996355A (en) | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
| US4049128A (en) | 1976-11-18 | 1977-09-20 | Westinghouse Air Brake Company | Control system for automatic railway car coupler |
| AU543727B2 (en) * | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| GB8803836D0 (en) | 1988-02-18 | 1988-03-16 | Glaxo Group Ltd | Compositions |
| JPH01249651A (ja) † | 1988-02-18 | 1989-10-04 | E I Du Pont De Nemours & Co | セラミツク／蒸留可能な結合剤組成物 |
| KR0159766B1 (ko) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
| JPH04230389A (ja) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| FI97472C (fi) * | 1991-05-07 | 1996-12-27 | American Home Prod | Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| SG47580A1 (en) | 1992-10-13 | 1998-04-17 | American Home Prod | Carbamates of rapamycin |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| RU2181054C2 (ru) * | 1994-11-02 | 2002-04-10 | Новартис Аг | Микроэмульсионный предконцентрат |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| PT956034E (pt) * | 1996-07-30 | 2002-12-31 | Novartis Ag | Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina |
| US6362264B1 (en) * | 1996-12-20 | 2002-03-26 | Ck Witco Corporation | Stabilizer for food contact and medical grade PVC |
| CA2279259A1 (en) | 1997-02-04 | 1998-08-06 | Abbott Laboratories | Pain reducing parenteral liposome formulation |
-
1998
- 1998-12-07 GB GBGB9826882.4A patent/GB9826882D0/en not_active Ceased
-
1999
- 1999-03-04 GB GBGB9904934.8A patent/GB9904934D0/en not_active Ceased
- 1999-11-29 CO CO99074905A patent/CO4980847A1/es unknown
- 1999-12-02 IT IT1999MI002520A patent/IT1319701B1/it active
- 1999-12-03 AR ARP990106171A patent/AR026102A1/es active IP Right Grant
- 1999-12-03 PE PE1999001209A patent/PE20001333A1/es not_active IP Right Cessation
- 1999-12-03 FR FR9915256A patent/FR2786771B1/fr not_active Expired - Lifetime
- 1999-12-04 TW TW088121250A patent/TWI248938B/zh not_active IP Right Cessation
- 1999-12-04 TW TW094104943A patent/TWI270550B/zh not_active IP Right Cessation
- 1999-12-06 RU RU2001118266/15A patent/RU2243769C2/ru active
- 1999-12-06 TR TR2001/01416T patent/TR200101416T2/xx unknown
- 1999-12-06 EP EP10179099A patent/EP2269651A3/en not_active Withdrawn
- 1999-12-06 SG SG200302502-0A patent/SG151072A1/en unknown
- 1999-12-06 SK SK766-2001A patent/SK286688B6/sk not_active IP Right Cessation
- 1999-12-06 PL PL348333A patent/PL196627B1/pl unknown
- 1999-12-06 JP JP2000586368A patent/JP3805625B2/ja not_active Expired - Lifetime
- 1999-12-06 EP EP06122628A patent/EP1743657A3/en not_active Ceased
- 1999-12-06 IL IL14309299A patent/IL143092A0/xx not_active IP Right Cessation
- 1999-12-06 AT AT99959381T patent/ATE365051T1/de active
- 1999-12-06 HU HU1300289A patent/HU230174B1/hu unknown
- 1999-12-06 CN CN2006100798040A patent/CN1876657B/zh not_active Expired - Lifetime
- 1999-12-06 CA CA2351580A patent/CA2351580C/en not_active Expired - Lifetime
- 1999-12-06 EP EP99959381A patent/EP1137439B2/en not_active Expired - Lifetime
- 1999-12-06 PT PT99959381T patent/PT1137439E/pt unknown
- 1999-12-06 DK DK99959381.7T patent/DK1137439T4/da active
- 1999-12-06 AU AU16573/00A patent/AU759219B2/en not_active Expired
- 1999-12-06 CZ CZ20050170A patent/CZ302210B6/cs not_active IP Right Cessation
- 1999-12-06 CA CA002651609A patent/CA2651609A1/en not_active Abandoned
- 1999-12-06 SK SK5032-2008A patent/SK287325B6/sk not_active IP Right Cessation
- 1999-12-06 KR KR1020017007009A patent/KR100695834B1/ko not_active Expired - Lifetime
- 1999-12-06 WO PCT/EP1999/009521 patent/WO2000033878A2/en not_active Ceased
- 1999-12-06 CZ CZ20012001A patent/CZ303006B6/cs not_active IP Right Cessation
- 1999-12-06 CN CNB998141240A patent/CN1261163C/zh not_active Expired - Lifetime
- 1999-12-06 SI SI9930985T patent/SI1137439T2/sl unknown
- 1999-12-06 CA CA2732620A patent/CA2732620C/en not_active Expired - Lifetime
- 1999-12-06 NZ NZ511936A patent/NZ511936A/en not_active IP Right Cessation
- 1999-12-06 HU HU0104489A patent/HU228939B1/hu unknown
- 1999-12-06 DE DE69936352T patent/DE69936352T3/de not_active Expired - Lifetime
- 1999-12-06 ID IDW00200101156A patent/ID29250A/id unknown
- 1999-12-06 HK HK02100663.4A patent/HK1038889B/en not_active IP Right Cessation
- 1999-12-06 EP EP10179096A patent/EP2279751A3/en not_active Withdrawn
- 1999-12-06 ES ES99959381T patent/ES2288033T5/es not_active Expired - Lifetime
- 1999-12-06 KR KR1020067017352A patent/KR20060096477A/ko not_active Ceased
- 1999-12-06 PL PL380082A patent/PL208854B1/pl unknown
- 1999-12-06 BR BR9915986-4A patent/BR9915986A/pt not_active Application Discontinuation
- 1999-12-06 TR TR2002/01428T patent/TR200201428T2/xx unknown
- 1999-12-07 MY MYPI20043386A patent/MY127579A/en unknown
- 1999-12-07 MY MYPI99005309A patent/MY120594A/en unknown
- 1999-12-07 BE BE9900799A patent/BE1012869A3/fr not_active IP Right Cessation
-
2001
- 2001-05-16 NO NO20012424A patent/NO332698B1/no not_active IP Right Cessation
- 2001-05-28 ZA ZA200104360A patent/ZA200104360B/en unknown
- 2001-05-29 US US09/866,977 patent/US6605613B2/en not_active Expired - Lifetime
-
2003
- 2003-03-21 US US10/393,795 patent/US6852729B2/en not_active Expired - Lifetime
- 2003-08-25 NZ NZ527781A patent/NZ527781A/en not_active IP Right Cessation
-
2004
- 2004-12-23 US US11/020,860 patent/US7297703B2/en not_active Expired - Lifetime
-
2005
- 2005-02-28 AR ARP050100744A patent/AR048073A2/es active IP Right Grant
- 2005-04-01 JP JP2005106512A patent/JP5043308B2/ja not_active Expired - Lifetime
- 2005-12-28 JP JP2005378514A patent/JP5165199B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-04 AR ARP060101807A patent/AR054444A2/es active IP Right Grant
-
2007
- 2007-09-14 CY CY20071101192T patent/CY1106870T1/el unknown
- 2007-10-11 US US11/973,927 patent/US7572804B2/en not_active Expired - Fee Related
-
2009
- 2009-07-06 US US12/497,728 patent/US7741338B2/en not_active Expired - Fee Related
-
2012
- 2012-10-01 NO NO20121113A patent/NO334612B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU230174B1 (hu) | Rapamycin-származékot tartalmazó ömlesztett keverék | |
| JPWO1999029708A1 (ja) | 結晶質アントラサイクリン抗生物質およびその製造方法 | |
| AU2003200370B2 (en) | Stabilization of macrolides | |
| MXPA01005720A (en) | Macrolides | |
| HK1146246A (en) | Stabilisation of macrolides | |
| HK1151741A (en) | Stabilisation of macrolides | |
| HK1102910A (en) | Stabilisation of macrolides |